



**HAL**  
open science

## Three-Year Outcomes in Kidney Transplant Recipients Switched From Calcineurin Inhibitor-Based Regimens to Belatacept as a Rescue Therapy

Antoine Morel, Léa Hoisnard, Caroline Dudreuilh, Anissa Moktefi, David Kheav, Ana Pimentel, Hamza Sakhi, David Mokrani, Philippe Attias, Karim El Sakhawi, et al.

### ► To cite this version:

Antoine Morel, Léa Hoisnard, Caroline Dudreuilh, Anissa Moktefi, David Kheav, et al.. Three-Year Outcomes in Kidney Transplant Recipients Switched From Calcineurin Inhibitor-Based Regimens to Belatacept as a Rescue Therapy. *Transplant International*, 2022, 35, pp.10228. 10.3389/ti.2022.10228 . hal-03759643

**HAL Id: hal-03759643**

**<https://hal.u-pec.fr/hal-03759643v1>**

Submitted on 24 Aug 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Three-year outcomes in kidney transplant recipients switched from calcineurin inhibitor-based regimens to belatacept as a rescue therapy**

Antoine Morel,<sup>1</sup> Léa Hoisnard,<sup>2,3\*</sup> Caroline Dudreuilh,<sup>1\*</sup> Anissa Moktefi,<sup>4,5</sup> David Kheav,<sup>6</sup> Ana Pimentel,<sup>1</sup> Hamza Sakhi,<sup>1</sup> David Mokrani,<sup>1</sup> Philippe Attias,<sup>1</sup> Karim El Sakhawi,<sup>1</sup> Cécile Maud Champy,<sup>7</sup> Philippe Remy,<sup>1,5</sup> Emilie Sbidian,<sup>2,3,8,9</sup> Philippe Grimbert,<sup>1,2,5,10</sup> Marie Matignon,<sup>1,5</sup>

\*Equally contributed to this work

1: AP-HP (*Assistance Publique-Hôpitaux de Paris*), *Hôpitaux Universitaires Henri Mondor*, Nephrology and Renal Transplantation Department, F-94010 *Créteil*, France

2: AP-HP (*Assistance Publique-Hôpitaux de Paris*), *Hôpitaux Universitaires Henri Mondor*, *Centre d'Investigation Clinique and Fédération Hospitalo-Universitaire TRUE (InnovaTive theRapy for immUne disordErs)*, F-94010 *Créteil*, France

3: *Université Paris Est Créteil (UPEC)*, *EpiDerME (Epidemiology in Dermatology and Evaluation of therapeutics)*, F-94010 *Créteil*, France

4: AP-HP (*Assistance Publique-Hôpitaux de Paris*), Pathology Department, *Groupe Hospitalier Henri-Mondor/Albert-Chenevier*, *Créteil*, F-94010, France

5: *Université Paris-Est Créteil*, *Institut National de la Santé et de la Recherche Médicale (INSERM) U955*, *Institut Mondor de Recherche Biomédicale (IMRB)*, F-94010 *Créteil*, France

6: AP-HP (*Assistance Publique-Hôpitaux de Paris*), *Laboratoire Régional d'histocompatibilité*, *Hôpital Saint Louis*, *1 avenue Claude Vellefaux*, 75010 Paris

7: AP-HP (*Assistance Publique-Hôpitaux de Paris*), *Hôpitaux Universitaires Henri Mondor*,  
Urology department, *Groupe Hospitalier Henri-Mondor/Albert Chenevier*, Créteil, F-94010,  
France

8: AP-HP (*Assistance Publique-Hôpitaux de Paris*), *Hôpitaux Universitaires Henri Mondor*,  
Department of Dermatology F-94010 Créteil, France

9: INSERM, *Centre d'Investigation Clinique 1430*, F-94010 Créteil, France

10: AP-HP (*Assistance Publique-Hôpitaux de Paris*), *Hôpitaux Universitaires Henri Mondor*,  
CIC biotherapy, F-94010 Créteil, France

### **Corresponding author contact**

Marie Matignon:

Nephrology and Transplant Department, Henri Mondor Hospital,

51 Avenue du Maréchal de Lattre de Tassigny

94000 Créteil, France

E-mail: [marie.matignon@aphp.fr](mailto:marie.matignon@aphp.fr)

Tel: +33 1 49 81 44 51

Fax: +33 1 49 81 24 52

**Running Title:** Rescue conversion from CNI to belatacept in kidney transplant recipients

**Table:** 5

**Figure:** 2

**Supplemental tables:** 4

**Word count:** abstract 200 words - main text 3602 words

**Keywords:** Kidney transplantation, belatacept, immunosuppression, anti HLA donor specific antibodies, calcineurin inhibitors

## **Abstract**

### *Background*

Long-term benefits of conversion from calcineurin inhibitors (CNIs) to belatacept in kidney-transplant recipients (KTr) are poorly documented.

### *Methods*

A single-center retrospective work to study first-time CNI to belatacept conversion as a rescue therapy (eGFR < 30 ml/min/1.73m<sup>2</sup>, chronic histological lesions, or CNI-induced thrombotic microangiopathy (TMA)). Patient and kidney allograft survivals, eGFR, severe adverse events, donor specific antibodies (DSA), and histological data were recorded over 36 months after conversion.

### *Results*

We included N=115 KTr. Switch leading cause was chronic histological lesions with non-optimal eGFR (56.5%). Three years after conversion, patient and death-censored kidney allograft survivals were 88% and 92%, respectively, eGFR increased significantly from 31.5±17.5 to 36.7±15.7 ml/min/1.73m<sup>2</sup> (P<0.01), rejection rate was 10.4%, OI incidence was 5.2 [2.9-7.6] per 100 person-years. Older age was associated with death, eGFR was not associated with death nor allograft loss. No patient developed *dn*DSA at M36 after conversion. CNI-induced TMA disappeared in all cases without eculizumab use. Microvascular inflammation and chronic lesions remained stable.

### *Conclusion*

Post-KT conversion from CNIs to belatacept, as a rescue therapy, is safe and beneficial irrespective of the switch timing and could represent a good compromise facing organ shortage. Age and eGFR at conversion should be considered in switch decision.

## Introduction

Despite improvement of kidney allograft short-term survival with conventional immunosuppressive agents, the allograft long-term survival has not increased as expected (1). One of the main reasons is the growing proportion of expanded criteria donor (ECD) in kidney transplantation (KT) (2). Calcineurin inhibitors (CNIs) are the standard long-term immunosuppression therapy in kidney transplant recipients (KTr) albeit it could contribute to acute and chronic impairment of kidney allograft function, especially in patients with chronic histological damage (2–5,6,8). Therefore, new immunosuppressive strategies are needed to preserve kidney allograft function and improve the graft long-term survival (6).

Belatacept is a CD80/CD86 – CD28 T-cell selective costimulation blocker developed to counteract CNI-induced nephrotoxicity. Two prospective randomized trials (BENEFIT and BENEFIT-EXT study) reported long-term safety and efficacy of *de novo* belatacept treatment coupled with improvement of estimated glomerular filtration rate (eGFR), and similar patient or kidney allograft survival in comparison with cyclosporine (8–11).

Since, growing evidence has suggested shifting KTr from CNIs-based regimen to belatacept, especially in those with low graft function or chronic histological lesions where belatacept is used as a rescue therapy (12–15). Additionally, it might be effective in sensitized kidney allograft recipients with preformed DSA (13–16). There is very little knowledge on the outcome of patients switched to belatacept after 1 year of follow-up, and often come from small sample cohorts, without DSA nor histological evolution analysis after the switch (8,16).

In this study, we assessed safety and tolerability of belatacept treatment as a rescue therapy up to three years after switching from CNIs. As well, we analyzed kidney allograft function, patients and kidney allograft survival, major outcomes after switching to belatacept and its effects on both DSA and kidney allograft histology changes.

## **Methods**

### ***Patients and study design***

In this retrospective monocentric study, we included all adults KTr converted for the first time from CNI-based immunosuppressive regimen to belatacept, from January 2012 to January 2019. Patients tested negative for EBV before transplantation, pregnant women, or women not on any contraceptive methods were not included since they were not eligible to receive belatacept treatment.

The KTr cohort was approved by IRB #00003835.

### ***Interventions***

Early and late conversion groups were defined according to the time of conversion from KT to first belatacept infusion: < 3 months or > 3 months, respectively. In early-stage conversion, CNIs were stopped at day 1 and KTr were given 10 mg/kg belatacept infusions at day 1, 5, 14, 28, and week 8 and 12, and then 5 mg/kg from week 16 onwards, every 4 weeks. In late-stage conversion, CNIs were stepped down to 50% at day 14 and stopped at day 28 after conversion, and belatacept infusions were given at 5 mg/kg at day 1, 14, 28, and then every 4 weeks thereafter (8).

### ***Study endpoints***

The primary endpoint was safety and tolerability of belatacept treatment. Major adverse events were defined as patient's death and kidney allograft loss. Follow-up continued till 30<sup>th</sup> of August 2021 or the date when a major adverse event occurred. Other severe adverse events (SAE) included community acquired infections requiring hospitalization, OIs, acute rejections, and neoplasia.

Secondary endpoints were: (i) eGFR and urine protein/creatinine ratio (UPCR) evolution up to three years after conversion, (ii) identification of different clusters of eGFR trajectory after conversion, (iii) metabolic parameters (LDL, HDL-cholesterol, triglycerides concentration,

HbA1C) and blood pressure profile evolution (iv) CMV or BK viremia, (v) pre-existing and *dn*DSA evolution and (vi) histological lesions evolution.

### ***Community acquired infection, opportunistic infection (OI) definitions and anti-microbial prophylaxis***

Community acquired infections were considered only in case of hospitalization. OIs were defined according to the current literature and international guidelines (18). OIs caused by the following pathogens were considered:

- Bacteria: *Mycobacterium* sp., *Listeria monocytogenes*, and *Nocardia* sp.
- Viruses: Cytomegalovirus (CMV), Varicella-Zoster virus (VZV), Human Herpes Virus-8 (HHV8), Norovirus, BK virus nephropathy, and JC virus.
- Fungi: *Candida* spp, *Cryptococcus* spp., invasive molds, and *Pneumocystis jirovecii*.
- Parasites: *Toxoplasma gondii*, *Microsporidium* sp, *Cryptosporidium* sp, *Leishmania* sp.

Patients were screened for BK viremia once a month during the first three months after KT, then every three months till the end of the first year, and every year till the end of year 5. After switching to belatacept, BKV was monitored every three months during the first year then once a year up to five years after KT. CMV prophylaxis followed the international guidelines: valganciclovir for 6 months in high-risk patients CMV D<sup>+</sup>/R<sup>-</sup> and 3 months in intermediate-risk patients CMV D<sup>+</sup>/R<sup>+</sup> or CMV D<sup>-</sup>/R<sup>+</sup> (19). *Pneumocystis* prophylaxis (Trimethoprim + Sulfamethoxazole) was administered during the first post-KT year.

### ***Variables***

Demographic characteristics, medical data, and laboratory samples, in particular eGFR, UPCR and DSA, were collected at the time of transplantation, at the time of conversion, and during belatacept treatment (3, 12, 24, 36, 48, and 60 months).

GFR was estimated using Modification of diet in renal disease (MDRD) formula (20).

Indications for switching to belatacept were recorded. Chronic histological lesions associated



with suboptimal allograft function was defined as eGFR < 30 ml/min/1.73m<sup>2</sup> and histological lesions associating ci+ct ≥ 3 and/or cv+ah ≥ 2.

Delayed graft function (DGF) was defined as the need for dialysis within 7 days after transplantation (21). Allograft loss was defined as the need for long-term dialysis and/or retransplantation.

### ***Anti-HLA antibody screening***

High-resolution DNA typing was performed in donors and recipients (HLA-A, HLA-B, Cw, HLA-DR, HLA-DQ or HLA-DP) at the time of KT. All serum samples were assessed for the presence of circulating preformed DSA and de novo DSA (*dn*DSA) on all HLA loci (HLA-A, HLA-B, Cw, HLA-DR, HLA-DQ or HLA-DP) at the time of KT, at conversion, at 3, 12, 24, 36, 48, and 60 months using high resolution Luminex SAB assay technology (One Lambda, Inc., Canoga Park, CA) on Luminex platform. All beads with MFI >1000 were considered positive (22). *Dn*DSA were considered positive if MFI was higher than 1000 at two time points.

Naturally existing DSA antibodies (*i.e.* presence of DSA in patients with no past immunizing events such as transfusion or pregnancy or having a previous transplant at the time of KT), as well as IgM DSA, were not considered in our study (23).

### ***Histological analysis***

Patients underwent for-cause or protocol kidney allograft biopsies. Acute and chronic histological lesions were described according to the updated Banff classification (24).

### ***Statistical analysis***

Continuous variables were presented in mean (standard deviation, SD) or median (Interquartile range, IQR) as appropriate, and categorical variables in number and percentage.

We used t-test or Wilcoxon test for continuous variables, and Chi-2 or Fisher exact tests for categorical variables. Paired t-test was used to compare quantitative variables at two different time-points. In patients who had at least two kidney biopsies (before and after conversion), paired comparisons of histological lesions were performed using Mc Nemar test or binomial test.

Time to death and to allograft loss, and survival without rejection after conversion (censored for death, kidney allograft loss, and belatacept withdrawal) were displayed with Kaplan Meier curves. Hazard ratios were estimated by Cox regression model. Incident rates of SAEs were estimated per 100 person-years (PY) with their confidence interval and the inter-group ratio of such incidence rate.

Sensitivity analyses of eGFR and proteinuria evolution after conversion to belatacept were performed with imputations of missing data regarding allograft loss (as 6 mL/min/1.73m<sup>2</sup>) alone then death and allograft loss together. However, data missed because of belatacept treatment interruption over the three year period were not imputed since the causes of interruption were multiple.

To identify clusters of eGFR trajectories, we used k-means method relying on expectation-maximization algorithms. Sensitivity analyses were performed for mean eGFR at different time points and eGFR trajectories. Missing data due to graft loss and/or death were imputed as 6 mL/min/1.73m<sup>2</sup>.

A p value <0.05 was considered significant. Tests were two-tailed. Statistical analyses were carried out using R 3.6.2.

## Results

From 01/2012 to 01/2019, 115 patients underwent first-time switch from CNI to belatacept, of whom 38 (33%) had early-stage switch, and 76 patients (66.1%) were males.

At the time of transplantation (**Table 1**), the mean age was  $55.8 \pm 15$  years old. Almost all donors were deceased (N=108 (93.9%)), mainly ECD (N=69 (60%)), and of  $61.5 \pm 15$  years old. All recipients received induction immunosuppressive therapy, such as anti-interleukin-2 receptor (N=61/115 (53%)), and N=11/115 (9.8%) had pretransplant DSA. Maintenance immunosuppressive therapy included CNIs (100%), mycophenolic acid (MPA) (82.6%), and steroids (100%). Of more, N=22/115 (19.1%) patients were at high risk for CMV transmission (D<sup>+</sup>/R<sup>-</sup>).

At the time of conversion (**Table 2**), 10 (2-27.5) months after KT, class I and II DSA were detected in 8/115 (7%) and 12/115 (10.4%) patients, respectively. In the late-switch group, the main cause of conversion was chronic vascular histological lesions associated with non-optimal kidney allograft function (71.4%), whereas it was prolonged DGF (55.3%) in the early-switch group. Concomitant immunosuppression is provided in **Table 2**. Median number of anti-hypertensive drugs was 2 (1-2), levels of HbA1c, LDL, and HDL-cholesterol were  $5.9 \pm 0.5$  %,  $2.1 \pm 0.5$  g/L and  $1 \pm 0.3$  g/L, respectively (**Table S3**).

### *Analysis at month 36*

The last follow-up checking was on 30<sup>th</sup> of August 2021. Recipients were followed over  $40.2 \pm 30.1$  months after conversion and n=58/115 (51%) completed 36 months of follow-up. Of the remaining 57 patients who did not reach the third years' time point, N=26/57 discontinued belatacept (alive with functional kidney allograft), N=13/57 died, N=9/57 lost their KT, N=8/57 did not complete 36 months, and N=1/57 was lost to follow-up. Three of the study patients (N=115; 2.6%), aged more than 70 years old, were treated for less than 3 months. The first developed BK virus nephropathy a month after conversion (blood BK virus replication >

6 log at the time of switch), hence the interruption of belatacept. The other two patients were switched to belatacept for arterial thrombosis and primary non function. Both developed rapid kidney allograft failure requiring renal replacement therapy and interruption of belatacept.

Three years after conversion, patient's and death-censored kidney allograft survival rates were respectively 88% and 92%, which dropped down to 81% and 89% at year 5 (**Figures 1.A and 1.B**). Overall graft survival was similar between groups (**Figure 1.C**). Age was the only significant risk factor for death after conversion in the univariate analysis (HR: 1.05 [1.01-1.1]). None of the other factors (conversion time from KT, gender, or eGFR) was significantly associated with death or allograft loss (**Table S1**). Estimated GFR significantly increased during the 36 months after conversion, from  $31.5 \pm 17.5$  to  $36.7 \pm 15.7$  ml/min/1.73m<sup>2</sup> (p<0.01). This significant increase was confirmed in the sensitivity analysis (p=0.05; **Table S2**). UPCR remained stable after conversion without and with sensitivity analysis (**Table S2**). HbA1c, HDL, and LDL-c serum levels significantly decreased over the 36 months after conversion (p<0.01 in all parameters; **Table S3**). Number of anti-hypertensive drugs and the triglycerides level remained stable (p=0.87 and p=0.39, respectively) (**Table S3**).

#### ***Major adverse events at the end of follow-up***

At the end of follow-up, 18/115 (16%) patients died, 12/115 (14%) had allograft failure, and 31/115 (26.9%) discontinued their treatment. The main causes of death were infection (N=11/115, 9.5%) including 3 cases of COVID-19, followed by cardiovascular diseases (N=6/115, 5.2%), and neoplasia (N=1/115, 0.9%). Allograft loss was mainly due to chronic allograft dysfunction (N=7/115, 6.1%); other causes implied primary non-function (N=3/115, 2.6%), chronic antibody mediated rejection (ABMR) (N=1/115, 0.9%), and BK virus nephritis (N=1/115, 0.9%).

The leading cause of belatacept discontinuation was OIs episodes (n=10/31, 32.3%), albeit no patient discontinued because of allograft loss or death. None of the 31 patients who had their

treatment interrupted died and N=6/31 (19.3%) lost their kidney allograft within 1 year after belatacept interruption. Reasons of kidney allograft loss in those were as follows: N=4/6 chronic dysfunction, N=1/6 acute ABMR, and N=1/6 severe focal and segmental glomerulosclerosis (FSGS).

### ***SAE at the end of follow-up***

At the end of follow-up, incidence of acute rejection was 10.4% (N=12/115). Two patients developed another rejection episode. The most common rejection mechanism was acute T-cell mediated (TCMR) (N=5/115, 4.3%), occurring within the first three months after conversion. Incidence was similar in early and late switch groups (20.0% and 9.8% respectively; p=0.14) (**Figure 1.D**). Evolution after rejection was as follows: (i) no patient died, (ii) all discontinued belatacept infusion except one case with borderline lesions and (iii) one kidney allograft loss within one year after conversion (refractory acute ABMR).

Incidence rates of OI and community acquired infections were 5.2 [2.9-7.6] and 15.6 [11.1-20] per 100 PY, respectively. The 19 OIs happened 10 (2-17) months after conversion and were mainly CMV disease (N=7/115, 6.1%) and pneumocystis pneumonia (N=5/115, 4.3%) (**Table 3**). BK viremia was reported in N=11/115 (10.8%) patients and CMV reactivation in N=27/115 (26.5%), especially in early conversion group (38.9% vs 17.1% in late conversion group, p=0.012). Among the N=19 OI patients, the infection caused the death of N=4/19 (21%), but no allograft loss was reported.

Malignancies were reported in 14/115 (12.2%) recipients, incidence rate was 3.9 [1.9-6.0] per 100 PY. Most of them had solid malignancy (N=8/115, 7%) and non-melanoma skin cancers (N=5/115, 4.3%). We documented one case of post-transplant lymphoproliferative disorder. Of the 14 cancer patients, none stopped belatacept treatment, one died of esophagus neoplasia within 6 months from diagnosis, and two lost their kidney allograft after chronic progressive kidney allograft dysfunction.

Incidence rate ratio between late and early switch groups were similar for all of the studied SAE (*e.g.* acute rejection, infections, and malignancies) (**Table 3**).

#### ***eGFR trajectories after conversion***

Two distinct eGFR trajectories were identified in the N=114 recipients after conversion (**Figure 2**): trajectory A in N=64/114 (56.1%) KTr and trajectory B in N=50/114 (43.9%). eGFR rapidly improved at three months and remained stable overtime in trajectory B. In trajectory A, eGFR progressively decreased after conversion. Cluster A recipients were more likely to have renal replacement therapy before KT ( $p<0.01$ ), previous KT ( $p=0.01$ ), eGFR  $< 30\text{ml}/\text{min}/1.73\text{m}^2$  at the time of conversion ( $<0.01$ ) (**Table S4**). Other characteristics (*i.e.* early or late switch, recipients' age, and histological characteristics before conversion) did not differ significantly between trajectory clusters.

#### ***Pre-existing and de novo DSA analysis***

Before the switch, DSA were detected in N=18/115 (15.7%) patients whose number remained stable over time after conversion (**Table 4**), though one developed chronic ABMR (N=1/18 (5.6%)). No patient developed *dn*DSA at the end of follow-up.

#### ***Histological analysis***

Among the 48 patients who underwent paired kidney allograft biopsies (**Table 5**), the second biopsy was performed 378 (182-802) days after conversion and in 60.1% were for-cause biopsies. Regarding acute tissue injuries, all CNI-associated acute thrombotic microangiopathy (TMA) lesions disappeared after conversion ( $p<0.001$ ). Microvascular inflammation (MVI) remained stable. As for the chronic lesions, all remained stable over time apart from the significant increase in tubular atrophy ( $p=0.04$ ).

## Discussion

We herein report a large monocentric cohort in a real-life situation where KT recipients were switched from CNI-based regimen to belatacept and followed for three years. In this cohort, belatacept safety was confirmed. At year 3, recipient and death-censored kidney allograft survivals reached almost 90%. Estimated GFR improved significantly over the 36-month period after conversion, regardless of the switch early or late timing. To our knowledge, our study is the second largest cohort studying CNIs-to-belatacept conversion as a rescue therapy with at least 3-year outcomes assessment, the longest follow-up currently available in this indication.

We observed a long-term benefit of CNIs-to-belatacept switch with significant improvement of kidney allograft function up to three years after the switch. Like other studies, eGFR significantly improved over the first three months, probably after suspending the hemodynamic effect of CNIs (8,13,14,25), and remained stable up to year 5 after conversion in our study. Long-term benefits of belatacept in kidney allograft recipients treated with *de novo* belatacept and no CNIs are well known (9,10). Recently, similar benefit has been demonstrated at 24 months after the switch in kidney allograft recipients, regardless of time after transplant and cause of switch (9–11,26,27). However, our KTr were older, sourced their grafts mainly from ECD, and had lower eGFR ( $<35$  ml/min/1.73m<sup>2</sup>) (26). UPCR remained stable after conversion without worsening as already described in short term follow-up studies (13). We also observed a long-term improvement of metabolic parameters such as the reduction in LDL cholesterol and HbA1C with stabilization of triglycerides concentration. Blood pressure remained stable after belatacept conversion. Other studies have already described such metabolic benefits (11,28) and their short-term stability after CNI-to-belatacept conversion, our results confirmed the long-term stability (13). The clinical outcome of these metabolic changes needs to be further investigated in much longer term studies.

In the whole cohort and in the late switch group, the leading cause of conversion was histological chronic vascular lesions associated with non-optimal kidney allograft function, whereas in the early switch group it was prolonged DGF. This real-life study design is different from that used in other studies which relied only on patients with stable eGFR (35-75 mL/min/1.73m<sup>2</sup>) (16). Here we confirmed that belatacept is a useful immunosuppressive agent at any time after transplantation and for any cause, even in patients with poor prognostic clinical features.

Recipient and kidney allograft survivals were up to 90% at year 3 after conversion and belatacept safety remained acceptable. Early and late switch groups had similar survivals, suggesting that belatacept could increase kidney allograft survival at any time after transplantation as in KTr with severe vascular lesions (15). Survival results reported in other studies varied according to KT recipients characteristics (14,16). In ours, age was the sole significant post-switch risk factor for death. eGFR level at switch was not a risk factor neither for death nor for graft loss, suggesting that conversion could be beneficial in all patients irrespective of their eGFR level. Age should be considered in the clinical decision and further research is warranted to investigate the effects of belatacept conversion in the elderly (*i.e.* > 70 years old).

OIs incidence in our cohort was comparable to previous published cohorts (29,30). Alike for OIs leading causes: CMV disease and pneumocystis pneumonia (29,30). Accordingly, we suggest maintaining CMV and Pneumocystis pneumonia prophylaxis in early conversion, close monitoring of CMV viremia, and considering pneumocystis pneumonia prophylaxis in case of lymphopenia (lymphocytes count <1000/mm<sup>3</sup>) (31). Infectious risk should always be considered upon deciding to switch. Similarly to other studies, the incidence of malignancies as well as the low occurrence of PTLD confirm the low risk of malignancies after belatacept treatment (16).



This is the largest cohort that focuses on kidney allograft histological evolution after conversion from CNI to belatacept. Around 60% of the second biopsies were for-cause. We observed TMA disappearance with no development of ABMR. The usefulness of CNI-to-belatacept conversion in patients with TMA has been described in few case reports (32–35). In our work, more than 10 TMA lesions vanished after switching to belatacept, suggesting that the latter alone might satisfy cost-effectiveness standards and be a safer strategy than if coupled with Eculizumab in recipients with TMA lesions (33). Post-switch biopsies showed no worsening in MVI ( $g + cpt \geq 2$ ) but precautions should be taken given the higher risk of allograft loss in these patients (36). Regarding chronic damages, we did not find significant variation over time except for tubular atrophy alone. Nevertheless, interstitial fibrosis and tubular atrophy (IFTA) remained stable, contrary to their tendency to worsen as described in a cohort of post-switch surveillance biopsies (37). Clinical outcomes such as eGFR might be a better predictor of graft outcomes as compared with IFTA ( $p=0.031$ ), which is consistent with eGFR improvement after belatacept conversion in our cohort (38). More data on CNI group comparison are still needed to assess kidney allograft histological modifications after conversion.

Considering immunological risks, switching our KTr to belatacept appeared to be safe as the prevalence of rejection was 10%. Similar results were observed in former studies even in sensitized patients (14,16). Acute rejection appeared quickly after conversion and almost all episodes were TCMR. Short CNI association could be considered especially in early conversion to avoid acute TCMR rejection risk (39). Despite acute rejection, allograft renal function improved significantly after three years. We also confirmed the low incidence of ABMR in recipients with preformed DSA treated with belatacept. DSA detected before the switch remained stable irrespective of other parameters and the incidence rate of *dn*DSA was null over five years after conversion. Similar 7-year incidence has been reported in BENEFIT

and BENEFIT-EXT studies with higher MFI threshold (*i.e.* > 2000) (40,41). The post-switch incidence of *dn*DSA was similar to former study (27). DSA detection technique and thresholds vary and can explain the differences in results (16,17,42). The low incidence of *dn*DSA with belatacept might be explained by the modulation of B-cell function, directly and at the level of B cell-Tfh interaction, incurring impairment of germinal center formation and improper antibody response in belatacept-treated KTr (43).

Despite some limitations including the monocentric, retrospective design and lack of control cohort, our study has several strengths: (i) 3-year post-switch follow-up in a real-life study design, (ii) including recipients with impaired kidney allograft function who were potentially not eligible for randomized studies, (iii) extensive data collection for each patient, from clinical characteristics to histological and DSA evolution. Data collection was exhaustive over a long follow-up interval.

In conclusion, we showed that in real life conditions, conversion from CNIs to belatacept, as a rescue therapy, is safe and beneficial in term of long-term kidney allograft preserved function. Patient and kidney allograft survivals were excellent 36 months after conversion with low incidence of SAE (acute rejection or infections). Immunological risk remained stable after conversion. CNI-to-belatacept switch should also be considered in CNI-treated recipients who develop TMA without ABMR, and could stabilize chronic histological lesions. Prospective studies are warranted to confirm those results.

**Acknowledgments:** We thank Ms. Tiphonie Londero, the manager of our local KTr follow-up database.

**Author contribution:**

M.M, L.H, and A.M conceptualized the study and analyzed data.

A.M, L.H, M.M, and P.G wrote the manuscript

A.M, L.H, C.D, A.M, D.K, H.S, D.M, P.A, K.ELS, C.C, P.R, E.S, P.G, and M.M participated in research design and data collection.

**Funding source:** None

**Conflict of Interest Statement:** All of the authors of this manuscript have no conflicts of interest to disclose.

## References

1. Coemans M, Süsal C, Döhler B, Anglicheau D, Giral M, Bestard O, et al. Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. *Kidney Int.* 2018 Nov;94(5):964–73.
2. Liefeldt L, Brakemeier S, Glander P, Waiser J, Lachmann N, Schönemann C, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.* 2012 May;12(5):1192–8.
3. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. *Clin J Am Soc Nephrol CJASN.* 2009 Dec;4(12):2029–34.
4. Nankivell BJ, Borrows RJ, Fung CL-S, O’Connell PJ, Allen RDM, Chapman JR. The natural history of chronic allograft nephropathy. *N Engl J Med.* 2003 Dec 11;349(24):2326–33.
5. Opelz G, Döhler B, Collaborative Transplant Study. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. *Transplantation.* 2009 Mar 27;87(6):795–802.
6. Bamoulid J, Staeck O, Halleck F, Khadzynov D, Brakemeier S, Dürr M, et al. The need for minimization strategies: current problems of immunosuppression. *Transpl Int.* 2015;28(8):891–900.
7. Leal R, Tsapepas D, Crew RJ, Dube GK, Ratner L, Batal I. Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation. *Kidney Int Rep.* 2017 Oct 27;3(2):281–90.
8. Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen Rial M, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. *Clin J Am Soc Nephrol CJASN.* 2011 Feb;6(2):430–9.
9. Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.* 2012 Jan;12(1):210–7.
10. Pestana JOM, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.* 2012 Mar;12(3):630–9.
11. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaithe L, et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. *N Engl J Med.* 2016 Jan 28;374(4):333–43.
12. Le Meur Y, Aulagnon F, Bertrand D, Heng AE, Lavaud S, Caillard S, et al. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.* 2016;16(7):2181–6.
13. Brakemeier S, Kannenkeril D, Dürr M, Braun T, Bachmann F, Schmidt D, et al. Experience with belatacept rescue therapy in kidney transplant recipients. *Transpl Int Off J Eur Soc Organ Transplant.* 2016 Nov;29(11):1184–95.
14. Darres A, Ulloa C, Brakemier S, Garrouste C, Bestard O, A DB, et al. Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study. *Transplantation.* 2018 Sep 1;102(9):1545–52.
15. Bertrand D, Cheddani L, Etienne I, François A, Hanoy M, Laurent C, et al. Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control

Study. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2017 Nov;17(11):2937–44.

16. Grinyó J, Del Carmen Rial M, Alberu J, Steinberg S, Manfro M, G N, et al. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial. *Am J Kidney Dis Off J Natl Kidney Found*. 2016 Nov 23;69(5):587–94.

17. Ulloa CE, Anglicheau D, Snanoudj R, Scemla A, Martinez F, Timsit M-O, et al. Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies. *Transplantation*. 2019;103(10):2150–6.

18. Attias P, Melica G, Boutboul D, De Castro N, Audard V, Stehlé T, et al. Epidemiology, Risk Factors, and Outcomes of Opportunistic Infections after Kidney Allograft Transplantation in the Era of Modern Immunosuppression: A Monocentric Cohort Study. *J Clin Med*. 2019 Apr 30;8(5).

19. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. *Transplantation*. 2018 Jun;102(6):900–31.

20. Levey AS, Stevens LA, Schmid CH, Zhang Y (Lucy), Castro AF, Feldman HI, et al. A New Equation to Estimate Glomerular Filtration Rate. *Ann Intern Med*. 2009 May 5;150(9):604–12.

21. Mannon RB. Delayed Graft Function: The AKI of Kidney Transplantation. *Nephron*. 2018;140(2):94–8.

22. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. *J Am Soc Nephrol JASN*. 2010 Aug;21(8):1398–406.

23. Ziemann M, Altermann W, Angert K, Arns W, Bachmann A, Bakchoul T, et al. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation. *Clin J Am Soc Nephrol CJASN*. 2019 Jul 5;14(7):1056–66.

24. Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2018;18(2):293–307.

25. Dürr M, Lachmann N, Zukunft B, Schmidt D, Budde K, Brakemeier S. Late Conversion to Belatacept After Kidney Transplantation: Outcome and Prognostic Factors. *Transplant Proc*. 2017 Oct;49(8):1747-1756.e1.

26. Gupta G, Raynaud M, Kumar D, Sanghi P, Chang J, Kimball P, et al. Impact of belatacept conversion on kidney transplant function, histology, and gene expression - a single-center study. *Transpl Int Off J Eur Soc Organ Transplant*. 2020 Aug 13;

27. Budde K, Prashar R, Haller H, Rial MC, Kamar N, Agarwal A, et al. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial. *J Am Soc Nephrol*. 2021 Dec 1;32(12):3252–64.

28. Durrbach A, Pestana JM, Florman S, Del Carmen Rial M, Rostaing L, Kuypers D, et al. Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2016 Nov;16(11):3192–201.

29. Bertrand D, Terrec F, Etienne I, Chavarot N, Sberro R, Gatault P, et al. Opportunistic Infections and Efficacy Following Conversion to Belatacept-Based Therapy after Kidney

- Transplantation: A French Multicenter Cohort. *J Clin Med* [Internet]. 2020 Oct 28 [cited 2021 Mar 30];9(11). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693007/>
30. Bertrand D, Chavarot N, Gatault P, Garrouste C, Bouvier N, Grall-Jezequel A, et al. Opportunistic infections after conversion to belatacept in kidney transplantation. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc*. 2020 01;35(2):336–45.
  31. Kaminski H, Belliere J, Couzi L, Kamar N, Merville P. Reply to Coussement et al. *Clin Infect Dis*. 2021 Aug 15;73(4):753–4.
  32. Ashman N, Chapagain A, Dobbie H, Raftery MJ, Sheaff MT, Yaqoob MM. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2009 Feb;9(2):424–7.
  33. Merola J, Yoo PS, Schaub J, Smith JD, Rodriguez-Davalos MI, Tichy E, et al. Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report. *Transplant Proc*. 2016 Nov;48(9):3106–8.
  34. Cicora F, Paz M, Mos F, Roberti J. Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy. *Case Rep Med*. 2013;2013:260254.
  35. Koppula S, Yost SE, Sussman A, Bracamonte ER, Kaplan B. Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients. *Clin Transplant*. 2013 Aug;27(4):591–7.
  36. Choi M, Bachmann F, Wu K, Lachmann N, Schmidt D, Brakemeier S, et al. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept. *BMC Nephrol*. 2020 Aug 20;21(1):354.
  37. Gupta G, Raynaud M, Kumar D, Sanghi P, Chang J, Kimball P, et al. Impact of belatacept conversion on kidney transplant function, histology, and gene expression - a single-center study. *Transpl Int*. 2020;33(11):1458–71.
  38. Loupy A, Aubert O, Orandi BJ, Naesens M, Bouatou Y, Raynaud M, et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. *BMJ*. 2019 Sep 17;366:l4923.
  39. Adams AB, Goldstein J, Garrett C, Zhang R, Patzer RE, Newell KA, et al. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2017 Nov;17(11):2922–36.
  40. Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, et al. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2018;18(7):1783–9.
  41. Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, et al. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2018 Jul;18(7):1774–82.
  42. Gombos P, Opelz G, Scherer S, Morath C, Zeier M, Schemmer P, et al. Influence of test technique on sensitization status of patients on the kidney transplant waiting list. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2013 Aug;13(8):2075–82.
  43. Leibler C, Thiolat A, Hénique C, Samson C, Pilon C, M T, et al. Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk. *J Am Soc Nephrol JASN*. 2018 Jan 10;29(3):1049–62.

## **Legend of figures**

### **Figure 1:**

**Figure 1.A:** Patient survival – **Figure 1.B:** Death-censored kidney allograft survival – **Figure 1.C:** Global survival (using a composite outcome of patient and death-censored kidney allograft survivals) – **Figure 1.D:** Survival without acute rejection (censored for death, kidney allograft loss, and belatacept withdrawal).

Kaplan-Meier method was used to assess patient survival from time of belatacept conversion (time 0). P-values were measured from log-rank test. X-axis: Post-conversion months. The blue curve represents the late switch group, whereas the red curve represents the early switch group. There was no statistical difference of patient, kidney allograft, global survival nor survival probability without rejection between early and late conversion groups using Cox analysis ( $p=0.54$ ,  $p=0.84$ ,  $p=0.73$ , and  $p=0.14$ , respectively).

**Figure 2:** Clusters of estimated glomerular filtration rate trajectories (A and B) in a subgroup of N=114 patients with at least one year of follow-up. Missing data were imputed at 6 ml/min for patients who died or lost their allograft. Trajectory A is represented by the red curve and trajectory B by the cyan curve.





**Table 1: Clinical and biological characteristics at the time of transplantation**

Variables	Whole cohort, N=115	Late switch, N=77	Early switch, N=38
<b>Recipient characteristics</b>			
Age, mean $\pm$ SD	55.8 (15.0)	53.9 (15.0)	60.0 (14.3)
Gender (Male), N (%)	76 (66.1)	51 (66.2)	25 (65.8)
Hemodialysis, N (%)	106 (92.2)	74 (96.1)	32 (84.2)
Previous KT, N (%)	15 (13.0)	13 (16.9)	2 (5.3)
<b>Initial nephropathy</b>			
Glomerulopathy, N (%)	24 (20.9)	15 (19.5)	9 (23.7)
Diabetes mellitus, N (%)	18 (15.7)	9 (11.7)	9 (23.7)
Nephroangiosclerosis, N (%)	11 (9.6)	8 (10.4)	3 (7.9)
Genetic, N (%)	10 (8.7)	8 (10.4)	2 (5.3)
Autoimmune disease, N (%)	4 (3.5)	3 (3.9)	1 (2.6)
Other, N (%)	22 (19.1)	15 (19.5)	7 (18.4)
Undetermined, N (%)	26 (22.6)	19 (24.7)	7 (18.4)
<b>Donor</b>			
Age, mean $\pm$ SD	61.5 (15)	60.6 (14.29)	63.4 (16.39)
Living donor, N (%)	7 (6.1)	5 (6.5)	2 (5.3)
Extended criteria donor, N (%)	69 (60)	46 (59.7)	23 (60.5)
<b>Donor/recipient CMV status</b>			
D+/R+, N (%)	51 (44.3)	36 (48.8)	15 (39.5)
D+/R-, N (%)	22 (19.1)	16 (20.8)	6 (15.8)
D-/R+, N (%)	34 (29.6)	21 (27.3)	13 (34.2)
D-/R-, N (%)	8 (7)	4 (5.2)	4 (10.5)
<b>Kidney transplant characteristics</b>			
Anti HLA donor specific antibodies, N (%)	11 (9.8)	6 (7.9)	5 (13.9)
Cold ischemia time, hours N=112, N (%)	18.1 (5.7)	18.2 (5.5)	17.7 (6)
Delayed graft function, N (%)	51 (44.3)	31 (40.3)	20 (52.6)
<b>Induction immunosuppressive therapy</b>			
Anti-interleukin 2 receptor, N (%)	61 (53)	42 (54.5)	19 (50)
Antithymocyte globulin, N (%)	54 (47)	35 (45.5)	19 (50)
<b>Maintenance immunosuppressive therapy</b>			
Calcineurin inhibitors, N (%)			
Cyclosporine	20 (17.4)	16 (20.8)	4 (10.5)
Tacrolimus	95 (82.6)	61 (79.2)	34 (89.5)
Mycophenolic acid (MPA), N (%)	95 (82.6)	66 (85.7)	29 (76.3)
mTOR inhibitors, N (%)	19 (16.5)	11 (14.3)	8 (21.1)
Steroids	115 (100)	77 (100)	38 (100)

KT: Kidney transplantation; mTOR: Mammalian target of rapamycin

**Table 2: Clinical and biological characteristics at the time of conversion**

KT: Kidney transplantation; eGFR: Estimated glomerular filtration rate; MPA: Mycophenolic acid; mTOR:

Variables	Whole cohort, N=115	Late switch, N=77	Early switch, N=38
Conversion time from KT, months, median (IQR)	10 (2-27.5)	17 (10-67)	1 (1-2)
Age, mean $\pm$ SD	58.6 (14.4)	57.5 (14.5)	60.8 (14.2)
<b>Reasons for switching</b>			
Prolonged delayed graft function, N (%)	23 (20)	2 (2.6)	21 (55.3)
Chronic histological lesions associated with suboptimal allograft function (ci+ct $\geq$ 3 and/or cv+ah $\geq$ 2), N (%)	65 (56.5)	55 (71.4)	10 (26.3)
Thrombotic microangiopathy, N (%)	21 (18.3)	17 (22.1)	4 (10.5)
Other renal causes, N (%)	4 (3.5)	1 (1.3)	3 (7.9)
Undetermined issues, N (%)	2 (1.7)	2 (2.6)	0 (0)
<b>Kidney allograft function</b>			
eGFR (mL/min/1.73m <sup>2</sup> ), mean $\pm$ SD	31.7 (17.8)	33.9 (16.9)	27.3 (19)
Urine protein/creatinine ratio > 100 mg/mmol, N (%)	29 (25.9)	15(19.7)	14 (38.9)
<b>Drugs</b>			
Antihypertensive drugs, median (IQR)	2 (1-2)	2 (1-2)	2 (1-2)
MPA, N (%)	104 (90.4)	69 (89.6)	35 (92.1)
500 mg per day, N (%)	12 (11.5)	11 (15.9)	1 (2.9)
1000 mg per day, N (%)	40 (38.5)	38 (55.1)	2 (5.7)
2000 mg per day, N (%)	40 (38.5)	9 (13.0)	31 (88.6)
Other dose, N (%)	12 (11.5)	11 (15.9)	1 (2.9)
mTOR inhibitors, N (%)	10 (8.7)	7(9.1)	3 (7.9)
T0 level (ng/mL), median (IQR)	5.2 (4.3-6.1)	4.5 (4.2-5.3)	6.3 (5.8-6.9)
Corticosteroids, N (%)	115 (100)	77 (100)	38 (100)
5 mg per day, N (%)	84 (73.0)	75 (97.4)	9 (23.7)
10 mg per day, N (%)	31 (27.0)	2 (2.6)	29 (76.3)
<b>Anti HLA donor specific antibodies</b>			
Class I, N (%)	8 (7)	6 (7.8)	2 (5.3)
Class II, N (%)	12 (10.4)	12 (15.6)	0 (0)
Both class I and class II, N (%)	2 (1.7)	2 (2.6)	0 (0)
None, N (%)	97 (84.3)	61 (79.2)	36 (94.7)
<b>Kidney biopsy (Banff lesions score)</b>			
Biopsy to conversion time, days, median (IQR)	N=102 35 (92-12)	N=77 48 (118-26)	N=25 8.5 (19.8-6.2)
<b>Acute tissue injury</b>			
Banff lesions score $\geq$ 1 in at least one compartment, N (%)	50 (48.5)	37 (48.1)	13 (50)
Acute tubular necrosis, N (%)	20 (19.2)	11 (14.3)	9 (33.3)
Glomerulitis (g), N (%)	7 (6.7)	7 (9.1)	0 (0)
Interstitial inflammation (i), N (%)	3 (2.9)	3 (3.9)	0 (0)
Tubulitis (t), N (%)	10 (9.6)	9 (11.7)	1 (3.7)
Peri-tubular capillaritis (cpt), N (%)	3 (2.9)	2 (2.6)	1 (3.7)
Vascular inflammation (v), N (%)	0 (0)	0 (0)	0 (0)
Thrombotic microangiopathy, N (%)	21 (19.6)	17 (22.1)	4 (13.3)
g + cpt ( $\geq$ 2), N (%)	9 (8.7)	8 (10.4)	1 (3.7)
<b>Chronic tissue injury</b>			
Banff lesions score $\geq$ 1 in at least one compartment, N (%)	97 (97)	74 (98.7)	23 (92)
Transplant glomerulopathy (cg), N (%)	8 (7.8)	8 (10.4)	0 (0)
Interstitial fibrosis (ci), N (%)	89 (87.3)	68 (89.5)	21 (80.8)
Total inflammation (ti), N (%)			
Tubular atrophy (ct), N (%)	84 (82.4)	66 (86.8)	18 (69.2)
Chronic vasculopathy (cv), N (%)	67 (65.7)	48 (63.2)	19 (73.1)
Arteriolar hyalinization (ah), N (%)	80 (79.2)	61 (81.3)	19 (73.1)
IFTA (ci + ct), N (%)	93 (92.1)	71 (93.4)	22 (88.0)
ci + ct + cg + cv, median (IQR)	4 (2-5)	4 (3-6)	4 (2-4)

Mammalian target of rapamycin; IFTA: Interstitial fibrosis and tubular atrophy

**Table 3: Serious adverse events after conversion, incidence rates per 100 person-years (PY) of treatment exposure**

Events	Whole cohort N=115 N (%)	Whole cohort N=115 Incidence per 100 PY [95% CI]	Late switch N=77	Early switch N=38	Incidence rate ratio [95% CI]
Rejections	12 (10.4)	3.5 [1.6-5.5]	2.6 [1.0-5.3]	6.1 [2.2- 13.3]	2.36 [0.66- 8.21]
Borderline	1 (0.9)				
Mixed	2 (1.8)				
Acute TCMR	5 (4.3)				
Acute ABMR	1 (0.9)				
Chronic ABMR	3 (2.6)				
<b>Infections</b>					
Community acquired infections	47 (40.9)	15.6 [11.1-20.0]	12.3 [8.2-17.8]	25.7 [15.5- 40.1]	2.08 [1.1-2.62]
Opportunistic infections	19 (16.5)	5.2 [2.9-7.6]	5.4 [3.1-8.8]	4.8 [1.8- 10.5]	0.89 [0.25- 2.62]
CMV disease	7 (6.1)				
Pneumocystosis	5 (4.3)				
VZV	4 (3.5)				
Other OI	3 (2.6)				
<b>Neoplasia</b>	14 (12.2)	3.9 [1.9-6.0]	3.8 [1.8-7.0]	4.3 [1.2- 10.9]	1.12 [0.26- 3.88]
Solid malignancy	8 (7.0)				
Non-melanoma skin cancer	5 (4.3)				
Post-transplant lymphoproliferative disorder	1 (1.0)				

**TCMR:** T cell-mediated rejection; **ABMR:** Antibody-mediated rejection; **CMV:** Cytomegalovirus; **VZV:** Varicella-Zoster-Virus; **OI:** Opportunistic infection; **PY:** Person-year; **CI:** Confidence interval

**Table 4: Preformed and *de novo* DSA evolution after conversion**

	Switch N (%) or median (Q1-Q3)	M3	M12	M24	M36	M48	M60
<b>Available data</b>	115	107	86	77	56	40	34
<b>DSA</b>							
<b>Pre-existing</b>	18 (15.7)	17/107 (17.2)	18/86 (20.9)	14/77 (18.2)	10/56 (17.9)	8/40 (20)	8/34 (23.5)
<b>DSA</b>							
Class I	8 (7)	7/107 (6.5)	4/86 (4.6)	5/77 (6.5)	2/56 (3.6)	2/40 (5)	3/34 (8.8)
Class I MFI max	2188 (1601- 2844)		1903 (1288-2569)		3302 (2876-3728)		
Class I MFI sum	2388 (1807- 3841)		2453 (2090-2569)		3302 (2876-3728)		
Class II	12 (10.4)	12/107 (11.2)	16/86 (18.6)	12/77 (15.6)	9/56 (16.2)	7/40 (1.8)	7/34 (20.6)
Class II MFI max	1769 (1433- 2951)		1472 (1201-3314)		3273 (1957-5092)		
Class II MFI sum	2920 (1642- 3178)		2027 (1292-4457)		3674 (1857-5277)		
<b>dnDSA appearance</b>	0	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

**dnDSA:** De novo Donor Specific Antibodies; **MFI:** Mean fluorescence intensity


**Table 5: Comparison of histological lesions before and after conversion**

Variables	Before switch, n=48	After switch, n=48	p-value
Time in days (median, IQR)	28 (9-71)	378 (182-802)	
<b>Acute tissue injury</b>			
Banff lesions score $\geq 1$ in at least one compartment, N (%)	23 (47.9)	30 (62.5)	
Acute tubular necrosis, N (%)	8 (16.7)	8 (16.7)	1
Glomerulitis (g), N (%)	4 (8.3)	5 (10.4)	1
Interstitial inflammation (i), N (%)	3 (6.2)	7 (14.6)	0.34
Tubulitis (t), N (%)	3 (6.2)	10 (20.8)	0.07
Peri-tubular capillaritis (cpt), N (%)	3 (6.2)	8 (16.7)	0.13
MVI (g+cpt $\geq 2$ ), N (%)	0 (0)	1 (2.1)	1
Thrombotic microangiopathy, N (%)	11 (22.9)	0 (0)	<b>&lt;0.001</b>
<b>Chronic lesions</b>			
Banff lesions score $\geq 1$ in at least one compartment, N (%)	47 (97.9)	48 (100)	
Transplant glomerulopathy (cg), N (%)	4 (8.3)	6 (12.5)	0.5
Interstitial fibrosis (ci), N (%)	43 (89.6)	48 (100)	0.06
Total inflammation (ti), N (%)	7 (14.6)	6 (12.5)	1
Tubular atrophy (ct), N (%)	40 (83.3)	47 (97.9)	<b>0.04</b>
Chronic vasculopathy (cv), N (%)	33 (68.8)	39 (81.2)	0.18
Arteriolar hyalinization (ah), N (%)	33 (68.8)	40 (83.3)	0.07
IFTA (ci + ct), median (IQR)	3 (2-3)	3 (2-3.25)	0.17


**MVI:** Micro-vascular inflammation

**Figure 1**


1.A




1.B



1.C




1.D





**Figure 2 :**



**eGFR** : Estimated glomerular filtration rate (ml/mn/1.73m<sup>2</sup>) from MDRD equation



## Supplemental digital contents

**Table supp 1: Evolution after conversion. Major events Cause-Specific Hazard Ratio (CSHR), for death and allograft loss**

	HR for deaths	p-value	HR for allograft loss	p-value
<b>Early or late switch groups</b>				
Late switch	1		1	
Early switch	1.36 [0.51-3.63]	0.54	0.88 [0.24-3.25]	0.84
<b>Gender</b>				
Female	1		1	
Male	0.78 [0.30-2.02]	0.61	0.51 [0.16-1.59]	0.24
<b>Age</b>				
Age at conversion (per 1Y increase)	1.05 [1.01-1.1]	<b>0.01</b>	1.03 [0.99-1.08]	0.12
<b>Renal function</b>				
eGFR (ml/mn/1.73m <sup>2</sup> )	1.02 [0.99-1.04]	0.18	0.98 [0.95-1.02]	0.39
eGFR < 30 ml/mn/1.73m <sup>2</sup>	0.81 [0.32-2.04]	0.65	0.81 [0.26-2.51]	0.71

1Y: 1 year ; eGFR: Estimated glomerular filtration rate (MDRD)

**Table supp 2: eGFR and UPCR evolution at different timepoints, with paired t-test analysis, with and without sensitivity analysis**

eGFR mL/min/1.73m <sup>2</sup>	At switch	3 months N=104	12 months N=86	24 months N=76	36 months N=62	48 months N=42	60 months N=34
Whole cohort mean (SD)	31.5 (17.5)	37.0 (17.5)	36.7 (13.7)	36.4 (14.5)	36.7 (15.7)	37.3 (16.3)	40.1 (16.2)
Paired mean of the differences*		+ 5.6	+ 5.4	+ 5.0	+ 5.4	+ 5.4	+ 5.5
P value		<b>&lt;0.01</b>	<b>&lt;0.01</b>	<b>&lt;0.01</b>	<b>&lt;0.01</b>	<b>&lt;0.01</b>	<b>0.01</b>
Sensitivity analysis**		N=105	N=89	N=80	N=67	N=48	N=41
Whole cohort mean (SD)	31.5 (17.5)	36.7 (17.7)	35.6 (14.6)	34.9 (15.7)	34.4 (17.1)	33.4 (18.5)	34.3 (19.7)
Paired mean of the differences*		+ 5.6	+ 4.7	+ 4.2	+ 3.9	+ 2.5	+ 1.2
P value		<b>&lt;0.01</b>	<b>&lt;0.01</b>	<b>0.01</b>	0.05	0.25	0.62
Sensitivity analysis***		N=109	N=98	N=90	N=81	N=67	N=61
Whole cohort mean (SD)	31.8 (17.5)	35.6 (18.3)	32.9 (16.3)	31.7 (17.3)	29.5 (19.0)	25.6 (20.0)	25.0 (20.9)
Paired mean of the differences*		+ 3.7	+ 1.0	+ 0.1	-3.2	-8.1	-10.1
P value		<b>0.02</b>	0.61	0.97	0.24	<b>0.01</b>	<b>&lt;0.01</b>

\* Paired mean of the difference with reference mean at time of switch

\*\* Analysis with imputation of missing values of allograft loss: 6 mL/min/1.73m<sup>2</sup>

\*\*\* Analysis with imputation of missing data of allograft loss and death: 6 mL/min/1.73m<sup>2</sup>

**Table supp 2 (continued)**

Urine protein/creatinine Ratio (UPCR)	At switch	3 months N=102	12 months N=86	24 months N=76	36 months N=62	48 months N=43	60 months N=34
Whole cohort UPCR > 100 mg/mmol N (%)	31 (27)	21 (20.6)	15 (17.4)	16 (13.9)	12 (10.4)	7 (6.1)	4 (11.8)
P-value		0.75	0.15	0.45	0.21	0.11	0.22

**Table supp 3: Metabolic parameters evolution 36-months after conversion**

<b>Variables</b>	<b>At time of switch</b>	<b>At 36 months</b>	<b>p-value</b>
Anti-hypertensive drugs, median (IQR)	2 (1-2)	2 (1-2)	0.87
HbA1C (%), mean ± SD	5.9 (0.5)	5.7 (0.4)	<b>&lt;0.01</b>
LDL-c (g/L), mean ± SD	2.1 (0.5)	1.9 (0.5)	<b>&lt;0.01</b>
HDL-c (g/L), mean ± SD	1 (0.3)	0.9 (0.3)	<b>&lt;0.01</b>
Triglycerides (g/L), median (IQR)	1.4 (1.2-2.2)	1.8 (1.2-2.3)	0.39

**Table supp 4: Comparison of patients characteristics according to eGFR trajectory clusters**

Variables	Cluster A N=64	Cluster B N=50	
<b>Recipient characteristics</b>			
Age, mean ± SD	56.4 (15.6)	56.0 (14.6)	0.88
Male gender, N (%)	38 (59.4)	37 (74.0)	0.10
Hemodialysis, N (%)	63 (98.4)	42 (84.0)	<b>0.01</b>
Previous kidney transplantation, N (%)	13 (20.3)	2 (4.0)	<b>0.01</b>
<b>Initial nephropathy</b>			
Glomerulopathy, N (%)	12 (18.8)	12 (24.0)	0.80
Diabetes mellitus, N (%)	9 (14.1)	9 (18.0)	
Hypertension, N (%)	8 (12.5)	3 (6.0)	
Genetic, N (%)	5 (7.8)	5 (10.0)	
Autoimmune disease, N (%)	1 (1.6)	2 (4.0)	
Other, N (%)	14 (21.9)	8 (16.0)	
Undetermined, N (%)	15 (23.4)	12 (24.0)	
<b>Donor characteristics</b>			
Age, mean ± SD	62.6 (14.2)	60.0 (16.0)	0.34
Extended criteria donor, N (%)	41 (64.1)	27 (54.0)	0.27
<b>Switch</b>			
Early, N (%)	21 (32.8)	17 (34.0)	0.89
eGFR mL/min/1.73m <sup>2</sup> , mean ± SD	26.4 (14.6)	36.4 (15.8)	<b>&lt;0.01</b>
eGFR <30 mL/min/1.73m <sup>2</sup> , N (%)	49 (76.6)	17 (34.0)	<b>&lt;0.01</b>
<b>Kidney biopsy (Banff lesions score)</b>			
Acute tissue injury			
Acute tubular necrosis, N (%)	12 (20.3)	8 (18.2)	0.78
Glomerulitis + Peri-tubular capillaritis ≥ 2, N (%)	1 (1.7)	2 (4.5)	0.60
Acute thrombotic microangiopathy, N (%)	10 (16.9)	10 (21.3)	0.30
Chronic lesions			
Transplant glomerulopathy, N (%)	5 (8.5)	3 (7.0)	1
Interstitial fibrosis + Tubular atrophy, N (%)	47 (82.5)	34 (79.1)	0.66
Chronic vasculopathy ≥ 2, N (%)	21 (36.2)	18 (41.9)	0.33
Arteriolar hyalinization + Chronic vasculopathy ≥ 2, N (%)	46 (80.7)	31 (72.1)	0.31